



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Trelagliptin-¹³C-d₃

Item No. 28203

Formal Name: (R)-2-((6-(3-aminopiperidin-1-yl)-3-(methyl-¹³C-d₃)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile
MF: C₁₇[¹³C]H₁₇D₃FN₅O₂
FW: 361.4
Chemical Purity: ≥98% (Trelagliptin)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₃); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Trelagliptin-¹³C-d₃ is intended for use as an internal standard for the quantification of trelagliptin (Item No. 18504) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Trelagliptin-¹³C-d₃ is supplied as a solid. A stock solution may be made by dissolving the trelagliptin-¹³C-d₃ in the solvent of choice. Trelagliptin-¹³C-d₃ is soluble in the organic solvent DMSO, which should be purged with an inert gas.

Description

Trelagliptin is an inhibitor of dipeptidyl peptidase 4 (DPP-4; IC₅₀ = 4 nM).¹ It is greater than 10,000-fold selective for DPP-4 over isopeptidases. Trelagliptin (7 mg/kg) inhibits plasma DPP-4 activity and reduces postprandial plasma insulin levels in Zucker *fa/fa* rats. Formulations containing trelagliptin have been used in the treatment of type 2 diabetes mellitus.

Reference

1. Kushwaha, R.N., Haq, W., and Katti, S.B. Discovery of 17 gliptins in 17-years of research for the treatment of type 2 diabetes: A synthetic overview. *Chemistry and Biology Interface* **4**(3), 137-162 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/18/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM